[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595545":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":29,"responsibleParty":43,"collaborators":45,"id":50,"slug":18,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":18,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":18,"studyType":62,"phases":63,"briefSummary":53,"conditions":65,"keywords":68,"overallStatus":32,"whyStopped":18,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Applied Biology, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Phenylephrine","EXPERIMENTAL","Topical Phenylephrine",[13],"Device: Phenylephrine",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"DEVICE",[9],null,[20],{"name":21,"affiliation":22,"role":23},"Andy Goren, MD","University of Rome G. Marconi","STUDY_DIRECTOR",[25],{"name":21,"role":26,"phone":27,"phoneExt":18,"email":28},"CONTACT","16507040850","clinicalstudies@appliedbiology.com",[30],{"facility":31,"status":32,"city":33,"state":18,"zip":18,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"University of Rome (\"G. Marconi\")","RECRUITING","Rome","Italy",{"type":36,"coordinates":37},"Point",[38,39],12.51133,41.89193,{"lat":39,"lon":38},[42],{"name":21,"role":26,"phone":27,"phoneExt":18,"email":28},{"type":44,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[46,48],{"name":47,"class":6},"Daniel Alain, Inc.",{"name":49,"class":6},"Follea International Limited","100595545",false,"NCT07033845","Pharmacokinetic Study of Topical Phenylephrine","Inclusion Criteria:\n\n* Healthy females, age 18-55\n* BMI: 18-30 kg\u002Fm²\n* Fitzpatrick Skin Types I-IV (to standardize absorption risk)\n* Scalp free from irritation, dermatologic disease, or damage\n* Able to refrain from using other topical scalp products\n\nExclusion Criteria:\n\n* History of cardiovascular disease, hypertension, or arrhythmia\n* Scalp infections, wounds, or significant hair loss\n* Recent use of medications that interfere with CYP enzymes or adrenergic systems\n* Known sensitivity to phenylephrine or ethanol\n* Positive drug screen or abnormal ECG at screening",true,"FEMALE","18 Years","55 Years",{"count":60,"type":61},24,"ESTIMATED","INTERVENTIONAL",[64],"EARLY_PHASE1",[66,67],"Chemotherapy Induced Alopecia","Chemotherapy Side Effects",[66,69],"Chemotherapy Alopecia","2025-09-30",{"date":72,"type":73},"2025-10-03","ACTUAL",{"date":75,"type":73},"2025-06-30",{"date":77,"type":61},"2025-12-28",{"name":5,"class":6},1]